Datieva V K, Rosinskaia A V, Levin O S
Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(7 Pt 2):77-81.
Chronic fatigue syndrome (CFS), a specific asthenic condition, is identified in a half of patients with Parkinson's disease (PD). An aim of the study was to evaluate an effect of melatonin (melaxen) on the severity of CFS, affective disorders, quality of life and sleep disorders in 30 patients with early and late stages of PD. After treatment, there was a decrease by 21% (p<0,05) on the Parkinson fatigue scale. At the same time, the improvement of sleep, assessed by the PDSS, decrease in the state anxiety on the Spilberger's scale and improvement of quality of life on the PDQ-39 (p<0,05) were found. No significant differences in motor, cognitive autonomic disorders and depression level were noted compared to baseline. Therefore, melatonin, together with optimized antiparkinsonian treatment, can treat CFS, improve sleep and quality of life of PD patients.
慢性疲劳综合征（CFS）是一种特定的虚弱状况，在半数帕金森病（PD）患者中被发现。本研究的目的是评估褪黑素（美拉酮）对30例早期和晚期PD患者的慢性疲劳综合征严重程度、情感障碍、生活质量和睡眠障碍的影响。治疗后，帕金森疲劳量表评分下降了21%（p<0.05）。同时，通过帕金森病睡眠量表（PDSS）评估发现睡眠得到改善，斯皮尔伯格量表上的状态焦虑降低，帕金森病问卷-39（PDQ-39）上的生活质量得到改善（p<0.05）。与基线相比，运动、认知自主神经障碍和抑郁水平无显著差异。因此，褪黑素与优化的抗帕金森治疗相结合，可以治疗慢性疲劳综合征，改善帕金森病患者的睡眠和生活质量。
